ライフサイエンスコーパス: CPMV

1 CPMV also exhibited clear treatment efficacy and systemi

2 CPMV nanoparticles are stable, nontoxic, modifiable with

3 onstrated, the specific interactions between CPMV and mammalian cells need to be characterized furthe

4 cancer cells (cervical, breast, and colon): CPMV nanoparticles enter cells via the surface marker vi

5 taining RNA-2, and of naturally-formed empty CPMV capsids.

6 ediated tumor angiogenesis using fluorescent CPMV provides a means to identify arterial and venous ve

7 eading to the development of dual-functional CPMV carrier systems.

8 Furthermore, CPMV-CD46 protected mice from mortality induced by an in

9 on of CPMV-BP is important to understand how CPMV is trafficked through the mammalian system and may

10 the Cowpea Mosaic Virus hypertranslational "CPMV-HT" expression system, which provides high yields o

11 As well as an intrinsic interest in CPMV as a plant pathogen, CPMV is of major interest in b

12 Cargo-infused CPMV nanoparticles remain chemically active, and surface

13 Inhaled CPMV nanoparticles were rapidly taken up by and activate

14 lian cells nevertheless bind and internalize CPMV in significant amounts.

15 hich allowed subgrouping of comoviruses into CPMV-like and BPMV-like viruses.

16 cy against a poorly immunogenic tumour, make CPMV an attractive and novel immunotherapy against metas

17 Although the bioavailability of CPMV in the mouse has been demonstrated, the specific in

18 Further characterization of CPMV-BP is important to understand how CPMV is trafficke

19 The CD46 peptide presented in the context of CPMV is also up to 100-fold more effective than the solu

20 ll assist further work in the development of CPMV as a biotechnological tool.

21 revious reports described the engineering of CPMV through genetic or chemical modification, we report

22 vide a useful means for functionalization of CPMV toward its application as drug and/or contrast agen

23 al to understand the in vivo interactions of CPMV within the mammalian system.

24 t although the host range for replication of CPMV is confined to plants, mammalian cells nevertheless

25 ory CD46 peptide expressed on the surface of CPMV retains virus-binding activity and is capable of in

26 rinsic interest in CPMV as a plant pathogen, CPMV is of major interest in biotechnology applications

27 ion of 130-155 fluorescent dye molecules per CPMV using DAPI (4',6-diamidino-2-phenylindole dihydroch

28 bitors showed that the CPMV binding protein (CPMV-BP) is not glycosylated.

29 Such CPMV-peptide chimeras can be easily and inexpensively pr

30 We show that CPMV nanoparticles can be used to visualize the vasculat

31 The CPMV-CD46 chimera efficiently inhibited MV infection of

32 A possible 47-kDa isoform of the CPMV-BP was also detected in the organelle and nuclear s

33 and glycosylation inhibitors showed that the CPMV binding protein (CPMV-BP) is not glycosylated.

34 This study utilized the CPMV chimera platform to create an antiviral against mea

35 ed through interaction of the cargo with the CPMV's encapsidated RNA molecules.

36 ctron microscopy (cryo-EM) maps of wild type CPMV containing RNA-2, and of naturally-formed empty CPM

37 tion of HeLa cells in vitro, while wild-type CPMV did not.

38 two other comoviruses, Cowpea mosaic virus (CPMV) and Bean pod mottle virus (BPMV).

39 The bioavailable cowpea mosaic virus (CPMV) can be fluorescently labeled to high densities wit

40 The plant virus cowpea mosaic virus (CPMV) has recently been developed as a biomolecular plat

41 Cowpea mosaic virus (CPMV) is a picorna-like plant virus.

42 like nanoparticles from cowpea mosaic virus (CPMV) reduces established B16F10 lung melanoma and simul

43 Cowpea mosaic virus (CPMV), a plant virus that is a member of the picornaviru

44 0), vaccinia (MVA), and cowpea mosaic virus (CPMV), were compared by AC capacitance scanning probe mi

45 specifically 30nm-sized cowpea mosaic virus (CPMV).

46 ottle virus (CCMV), and cowpea mosaic virus (CPMV).